Retatrutide, a novel dual agonist of the GLP-1 target and glucose-dependent released polypeptide (GIP) target, is showing promising outcomes in preliminary clinical studies. Recent examination suggests https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/